Literature DB >> 2550453

An antibody-induced enhancement of the transducin-stimulated cyclic GMP phosphodiesterase activity.

W J Phillips1, S Trukawinski, R A Cerione.   

Abstract

In this work we have characterized the ability of a carboxyl peptide-specific antibody (AS/7), raised against the alpha subunit of transducin (alpha T), to potentiate the stimulation of the cyclic GMP phosphodiesterase (PDE) by transducin. The complexation of the purified guanosine 5'-O-(3-thiotriphosphate) (GTP gamma S)-bound form of alpha T (alpha T.GTP gamma S) with AS/7 results in a 2-5-fold enhancement in the total levels of cyclic GMP hydrolysis measured after 1 min. This potentiation by AS/7 cannot be attributed simply to an increase in the apparent affinity of alpha T.GTP gamma S for the effector enzyme, nor to an increased affinity of the enzyme for the substrate cyclic GMP. The AS/7-induced potentiation is specific for alpha T.GTP gamma S-PDE interactions; this antibody has no effect on the activity of the trypsin-activated PDE nor on the ability of the GDP-bound form of alpha T to inhibit the trypsin-activated enzyme (Kroll, S., Phillips, W. J., and Cerione, R. A. (1989) J. Biol. Chem. 264, 4490-4497). Phosphatidylcholine vesicles also will enhance the alpha T.GTP gamma S-stimulated PDE activity (1.5-2-fold) relative to that measured in the absence of a lipid milieu. However, the potentiations of alpha T-stimulated cyclic GMP hydrolysis elicited by AS/7 and lipids represent separate events. Titration profiles describing the AS/7-induced potentiation, as a function of the amount of antibody added to the assay mixtures, indicate that maximal activity occurs when there is one molecule of AS/7 per two molecules of alpha T.GTP gamma S; the AS/7-induced potentiation is lost when AS/7 much greater than alpha T. GTP gamma S, i.e. conditions which favor the formation of monovalent AS/7-alpha T.GTP gamma S complexes. When the AS/7 is papain-treated to yield monovalent antibody molecules, complexation between these monovalent antibodies and alpha T still occurs (as reflected by the ability of these antibodies to block rhodopsin-alpha T coupling); however, the potentiation of the alpha T.GTP gamma S-stimulated PDE activity is lost. Taken together, these results suggest that the AS/7-induced potentiation of alpha T-stimulated activity is dependent on the bivalent nature of the antibody, and maximal stimulation of PDE activity is achieved by the interactions of two activated-alpha T molecules with a single molecule of PDE.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2550453

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  5 in total

1.  Mechanism for the regulation of mammalian cGMP phosphodiesterase6. 2: isolation and characterization of the transducin-activated form.

Authors:  Akio Yamazaki; Masahiro Tatsumi; Vladimir A Bondarenko; Sadamu Kurono; Naoka Komori; Hiroyuki Matsumoto; Isao Matsuura; Fumio Hayashi; Russell K Yamazaki; Jiro Usukura
Journal:  Mol Cell Biochem       Date:  2010-02-23       Impact factor: 3.396

2.  A C-terminal peptide of bovine rhodopsin binds to the transducin alpha-subunit and facilitates its activation.

Authors:  W J Phillips; R A Cerione
Journal:  Biochem J       Date:  1994-04-15       Impact factor: 3.857

3.  The G-protein-coupled receptor phosphatase: a protein phosphatase type 2A with a distinct subcellular distribution and substrate specificity.

Authors:  J A Pitcher; E S Payne; C Csortos; A A DePaoli-Roach; R J Lefkowitz
Journal:  Proc Natl Acad Sci U S A       Date:  1995-08-29       Impact factor: 11.205

4.  Structure of the Visual Signaling Complex between Transducin and Phosphodiesterase 6.

Authors:  Yang Gao; Gözde Eskici; Sekar Ramachandran; Frédéric Poitevin; Alpay Burak Seven; Ouliana Panova; Georgios Skiniotis; Richard A Cerione
Journal:  Mol Cell       Date:  2020-10-01       Impact factor: 17.970

5.  Novel regulatory mechanisms for the Dbl family guanine nucleotide exchange factor Cool-2/alpha-Pix.

Authors:  Qiyu Feng; Daniel Baird; Richard A Cerione
Journal:  EMBO J       Date:  2004-08-12       Impact factor: 11.598

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.